Immix biopharma announces positive u.s. clinical data from first four patients in nexicart-2 u.s. trial of sterically-optimized car-t nxc-201 in relapsed/refractory light chain (al) amyloidosis

All four patients treated with nxc-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (cr), and the remaining two are bone marrow mrd negative (10-6); all patients remain in response as of the data cutoff of nov 14, 2024 bone marrow mrd negativity predicts future cr; company believes remaining two patients could be confirmed as crs in the coming weeks and months company to provide next program update in h1 2025 conference call to discuss results dec 19 at 11:00 a.m. et (link to attend) los angeles, ca, dec. 19, 2024 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us” or ”immx”), a clinical-stage biopharmaceutical company developing cell therapies for al amyloidosis and select immune-mediated diseases, today announced initial clinical data from the first four patients in the ongoing nexicart-2 (nct06097832) u.s. study of sterically-optimized bcma-targeted chimeric antigen receptor t (car-t) cell therapy, nxc-201, in relapsed/refractory al amyloidosis.
AL Ratings Summary
AL Quant Ranking